The company and Canada have been at odds for more than a year over patents for Straterra and Zyprexa. Lilly claims the patents were unfairly invalided by Canadian courts after challenges by generic manufacturers. The Indianapolis biotech company says the standards in Canada's legal system has set too high of a standard for original manufacturers to secure patents.